α‐Synuclein pathology in the cranial and spinal nerves in Lewy body disease

Abstract

Accumulation of phosphorylated α-synuclein in neurons and glial cells is a histological hallmark of Lewy body disease (LBD) and multiple system atrophy (MSA). Recently, filamentous aggregations of phosphorylated α-synuclein have been reported in the cytoplasm of Schwann cells, but not in axons, in the peripheral nervous system in MSA, mainly in the cranial and spinal nerve roots. Here we conducted an immunohistochemical investigation of the cranial and spinal nerves and dorsal root ganglia of patients with LBD. Lewy axons were found in the oculomotor, trigeminal and glossopharyngeal-vagus nerves, but not in the hypoglossal nerve. The glossopharyngeal-vagus nerves were most frequently affected, with involvement in all of 20 subjects. In the spinal nerve roots, Lewy axons were found in all of the cases examined. Lewy axons in the anterior nerves were more frequent and numerous in the thoracic and sacral segments than in the cervical and lumbar segments. On the other hand, axonal lesions in the posterior spinal nerve roots appeared to increase along a cervical-to-sacral gradient. Although Schwann cell cytoplasmic inclusions were found in the spinal nerves, they were only minimal. In the dorsal root ganglia, axonal lesions were seldom evident. These findings indicate that α-synuclein pathology in the peripheral nerves is axonal-predominant in LBD, whereas it is restricted to glial cells in MSA.

Health benefits of methylxanthines in neurodegenerative diseases

“…Some types of this pathophysiologically heterogeneous disease seem to be linked to mutations in the gene encoding α‐synuclein that lead to the aggregation of this protein into Lewy bodies. These intracellular inclusions are similar to those found in PD, but unlike in PD, they are preferentially located in cortical and subcortical areas of the brain . It is estimated that DLB causes up to 22.8% of dementias, but the percentage might be underestimated due to their AD/PD‐like symptoms, which compromise accurate diagnosis .…”

Review: Sporadic Parkinson's disease: development and distribution of α‐synuclein pathology

“…We formerly speculated that an environmental or neurotropic pathogen might adhere to the mucous membrane of the upper gastrointestinal tract and/or nose and penetrate into neuronal processes of neurons there, where it might trigger a conformational change in α ‐synuclein. Then, via transneuronal and retrograde axonal transport along unmyelinated axons of the vagal nerve, α ‐synuclein aggregates from the ENS could reach the preganglionic neurons of the dorsal motor nucleus of the vagal nerve . Inasmuch as the vagus nerve exerts its influence chiefly on the distal portions of the oesophagus and following proximal portions of the stomach , these regions are among the more likely sites for a transfer and propagation of small α ‐synuclein aggregates between interconnected neurons.…”

Atrophy of the Vagus Nerve in Parkinson's Disease Revealed by High-Resolution Ultrasonography

“…In animal models, α-synuclein derived from human PD brain lysate and distinct recombinant α-synuclein forms are transported via the vagal nerve and reach the dmX in a time-dependent manner after injection into the intestinal wall ( 4 ). Axonal-predominant α-synuclein pathology has also been found in the glossopharyngeal-vagus and spinal nerve roots as well as in cervical and pharyngeal sections of the vagus nerve in PD patients ( 5 , 6 ). However, it is still unknown whether the neurodegenerative process in PD is also associated with measurable atrophy of the vagus nerve in vivo .…”